Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01988116 · ClinicalTrials.gov registry record · Early Phase 1
Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease
A Early Phase 1 study of Chronic Kidney Disease and Anemia of Chronic Disease, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT01988116: Completed Early Phase 1 study of Chronic Kidney Disease and Anemia of Chronic Disease, sponsored by University of Alabama at Birmingham.
NCT01988116 is a Early Phase 1 study of Chronic Kidney Disease and Anemia of Chronic Disease that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 40 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01988116, a Early Phase 1 study of Chronic Kidney Disease and Anemia of Chronic Disease, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to learn more about how treatment with vitamin D can affect iron metabolism and blood levels of two hormones that control iron levels, hepcidin and hemojuvelin in people with chronic kidney disease (CKD). Iron is an essential mineral which is a major component of proteins that carry oxygen in the blood. Problems with iron metabolism can lead to low blood levels (anemia), which can commonly happen in people with CKD. New research over the last decade has uncovered a new hormone called 'hepcidin', which is made in the liver and released into the blood. Hepcidin controls how much iron is in the blood by preventing the absorption of iron from food. Blood levels of hepcidin C are found to be high in people with CKD, and a recent small study in people with normal kidney function showed that treatment with vitamin D decreased hepcidin levels. Another protein, known as 'hemojuvelin', has been recently discovered and is also thought to control the amount of iron in the blood. The relationship between vitamin D and hemojuvelin has never been studied before. In this study, investigators would like to examine the effects of vitamin D on iron metabolism and blood levels of hepcidin C and hemojuvelin in individuals with CKD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oral Calcitriol 0.5 mcg once daily for 6 weeks
Study Locations (1)
Alabama
- University of Alabama - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-06 |
| Phase | Early Phase 1 |
What the finished NCT01988116 record still lists
NCT01988116 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01988116 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT01988116 about?
NCT01988116 is a clinical study titled "Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease". The purpose of the study is to learn more about how treatment with vitamin D can affect iron metabolism and blood levels of two hormones that control iron levels, hepcidin and hemojuvelin in people with chronic kidney disease (CKD). Iron is an essential mineral which is a major component of protein...
What is the current status of trial NCT01988116?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2013-10. Estimated completion is 2015-06.
What conditions does trial NCT01988116 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Anemia of Chronic Disease.
What interventions are being tested in trial NCT01988116?
The interventions under investigation include: Placebo (DRUG), Oral Calcitriol 0.5 mcg once daily for 6 weeks (DRUG).
Who is sponsoring clinical trial NCT01988116?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01988116 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01988116's enrollment target sits among peer trials
40 78th of 101 higher than 24 of 101 other Chronic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD
COMPLETED · Early Phase 1
-
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
RECRUITING · Phase 2
-
Patient-driven Management of BP in CKD
RECRUITING · Phase 3
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
Safety of Short-course of NSAIDs in Pediatric Patients With CKD
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia